Press Releases
RADNOR, Pa. – November 13, 2023 – Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, has expanded its cell science offerings to include MULTISCREENTM cell lines, membranes and custom cell engineering & assay services from Multispan, Inc.
The new offerings support the needs of the rapidly growing cell and gene therapy market, as well as other life science research markets. Avantor’s life sciences customers will have access to Multispan’s proprietary stable cell lines, cell membranes, as well as custom cell engineering and cellular assay services.
“Avantor is committed to providing our customers with products, materials and services that help to accelerate life-changing therapeutics. Cell and gene therapies are a rapidly growing area that holds great promise and we are excited to include Multispan in our portfolio for customers in the U.S., Canada and Europe,” said Frederic Vanderhaegen, Executive Vice President of Europe at Avantor.
“Multispan is deeply committed to providing expertise and reliable, best-in-class products to researchers. Our relationship as a supplier to Avantor enables our broad range of proprietary products and custom services to readily reach a vast network of scientists and researchers and help accelerate their drug discovery research,” said Helena Mancebo, Ph.D., Founder and CEO of Multispan, Inc.
CRISPR gene editing, stem cells, AI-enabled drug discovery, and other new technologies are propelling changes in the way new drugs and therapies are developed.
MULTISCREENTM cell lines, membranes and custom cell engineering & assay services will be available to purchase through Avantor’s leading global e-commerce platform, as well as through its direct regional sales force.
About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the life sciences and technology industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
About Multispan
Multispan, Inc. is a leader in cell engineering, HTS assay development and in vitro pharmacology screening, with a solid track record in shortening the target to IND timeline and lowering costs. Multispan offers potency cell line engineering and assay development services and > 2000 target-specific assays to jump start drug discovery programs. Multispan’s portfolio consists of vast HTS-ready assays for GPCRs and other drug targets with 560+ MULTISCREEN™ All-Assays-in-One-Cell-Lines. Multispan’s dedicated team of assay experts based in the San Francisco Bay Area has helped move numerous drugs into the clinic from target to IND with quality and speed. Our mission is to help enable better medicine, one assay a time. For more information, visit multispaninc.com and find us on LinkedIn.
Avantor Contact
Kristopher Akana
Director, Communications
Avantor
+33 (0)1 45 14 83 59
Kristopher.akana@avantorsciences.com
Multispan Contact
Gary Zweiger, PhD
Head of Business Development
Multispan Inc.
(650) 799-1253
gary.zweiger@multispaninc.com